Neurocrine Biosciences, Inc. (NBIX) Earnings History
Profitable30 years of earnings data (1996–2025) · Positive TTM net income
Loading earnings history...
Neurocrine Biosciences, Inc. (NBIX) Earnings Overview
As of June 30, 2026, Neurocrine Biosciences, Inc. (NBIX) reported trailing twelve-month net income of $669M, reflecting +41.9% year-over-year growth. The company earned $6.47 per diluted share over the past four quarters, with a net profit margin of 16.7%.
Looking at the long-term picture, NBIX's 5-year EPS compound annual growth rate (CAGR) stands at +2.3%, reflecting modest earnings expansion. The company achieved its highest annual net income of $479M in fiscal 2025, representing a new all-time high.
Neurocrine Biosciences, Inc. maintains industry-leading profitability with a gross margin of 98.2%, operating margin of 21.6%, and net margin of 16.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), ACAD ($376M net income, 36.5% margin), PTCT (-$187M net income, 39.4% margin), NBIX has room to improve margins relative to the peer group. Compare NBIX vs INVA →
NBIX Earnings vs Peers
Earnings metrics vs comparable public companies
NBIX Historical Earnings Data (1996–2025)
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $479M | +40.2% | $619M | $4.67 | 16.7% | 21.6% |
| 2024 | $341M | +36.7% | $571M | $3.29 | 14.5% | 24.2% |
| 2023 | $250M | +61.6% | $251M | $2.47 | 13.2% | 13.3% |
| 2022 | $155M | +72.4% | $249M | $1.56 | 10.4% | 16.7% |
| 2021 | $90M | -78.0% | $103M | $0.92 | 7.9% | 9.0% |
| 2020 | $407M | +1000.8% | $163M | $4.16 | 38.9% | 15.6% |
| 2019 | $37M | +75.3% | $72M | $0.39 | 4.7% | 9.2% |
| 2018 | $21M | +114.8% | $37M | $0.22 | 4.7% | 8.2% |
| 2017 | -$143M | -1.0% | -$131M | $-1.62 | -88.2% | -81.3% |
| 2016 | -$141M | -58.7% | -$147M | $-1.63 | -940.6% | -982.5% |
| 2015 | -$89M | -46.9% | -$94M | $-1.05 | -449.8% | -476.5% |
| 2014 | -$61M | -31.4% | -$64M | $-0.81 | - | - |
| 2013 | -$46M | -1017.2% | -$50M | $-0.69 | -1579.0% | -1701.9% |
| 2012 | $5M | -86.6% | $1M | $0.08 | 9.5% | 2.7% |
| 2011 | $38M | +571.5% | $34M | $0.67 | 48.5% | 43.8% |
| 2010 | -$8M | +84.4% | -$14M | $-0.15 | -23.8% | -41.0% |
| 2009 | -$51M | +42.4% | -$54M | $-1.30 | -1728.3% | -1817.5% |
| 2008 | -$89M | +57.3% | -$87M | $-2.30 | -2229.3% | -2196.2% |
| 2007 | -$207M | -93.4% | -$212M | $-5.45 | -16936.2% | -17340.0% |
| 2006 | -$107M | -383.1% | -$113M | $-2.84 | -273.2% | -288.8% |
| 2005 | -$22M | +51.5% | -$25M | $-0.58 | -17.9% | -20.2% |
| 2004 | -$46M | -51.3% | -$52M | $-1.26 | -53.7% | -61.4% |
| 2003 | -$30M | +68.0% | -$59M | $-0.93 | -21.8% | -42.3% |
| 2002 | -$95M | -156.1% | -$104M | $-3.10 | -523.9% | -574.2% |
| 2001 | -$37M | -28.1% | -$44M | $-1.42 | -89.5% | -106.4% |
| 2000 | -$29M | -71.5% | -$36M | $-1.30 | -197.5% | -244.0% |
| 1999 | -$17M | +16.0% | -$20M | $-0.88 | -100.0% | -118.5% |
| 1998 | -$20M | -492.2% | -$12M | $-1.10 | -125.0% | -77.5% |
| 1997 | $5M | -13.6% | $500,000 | $0.28 | 19.5% | 1.9% |
| 1996 | $6M | - | $3M | $0.36 | 30.7% | 15.1% |
Download Data
Export NBIX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
30+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBIX — Frequently Asked Questions
Quick answers to the most common questions about buying NBIX stock.
What is NBIX earnings per share (EPS)?
NBIX trailing twelve-month (TTM) diluted EPS is $6.47, reflecting +41.9% year-over-year growth. The 5-year EPS CAGR is +2.3%. Complete EPS history from 1996 to 2025 is available in the table on this page.
What is Neurocrine Biosciences, Inc.'s net income?
Neurocrine Biosciences, Inc. (NBIX) trailing twelve-month net income is $669M as of 2025. Earnings grew +41.9% year-over-year. Neurocrine Biosciences, Inc. has been profitable for 8 consecutive years.
Is NBIX profitable?
Yes, NBIX is profitable with a TTM net income of $669M and a net profit margin of +16.7%. Neurocrine Biosciences, Inc. has generated profits for 8 consecutive years.
What is NBIX's earnings growth rate?
NBIX compound annual EPS growth rates (CAGR): 1-Year: +41.9%, 3-Year: +44.1%, 5-Year: +2.3%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1996 to 2025.
What are NBIX's profit margins?
Neurocrine Biosciences, Inc. net profit margin is +16.7%, operating margin is +21.6%, and gross margin is +98.2%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +16.4%.
Is NBIX growing earnings?
Yes, NBIX earnings are accelerating — EPS growth of +41.9% exceeds the 5-year CAGR of +2.3%. TTM net income reached $669M. Earnings momentum is strengthening.
What was NBIX's best earnings year?
Neurocrine Biosciences, Inc.'s highest annual net income on record is $479M, achieved in fiscal year 2025. Earnings history on this page spans 1996 to 2025 and includes all annual and quarterly figures.
What were NBIX's earnings last quarter?
NBIX's most recent reported quarter was Q1 2026. Net income was $198M with diluted EPS of $1.91. For a full breakdown of all quarters, see the quarterly earnings table on this page.